Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 20;15:1531. doi: 10.1038/s41467-024-45817-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Schematic of domain structure of SEL1L protein. FN2 = Fibronectin-2. b Flow-cytometry based collagen-uptake assay in MRC5 lung fibroblasts after treatment with lentiviral-mediated shRNA against SEL1L or Scramble control. N = 3 per group, p = 0.0359. c, d Western blot and densitometry of MRC5 lung fibroblasts after shRNA treatment as indicated vs. Scramble control, representative of N = 3 independent experiments; p = 0.0102. e Flow-cytometry based collagen-uptake assay in MEF cells (mouse embryonic fibroblasts) after treatment with 4-hydroxytamoxifen (OHT) as indicated vs. vehicle control. WT = Sel1L^f/f;ERcre-, iKO = Sel1L^f/f;ERcre+. N = 4 (OHT condition), 3 (veh condition) per group; p = 0.0018 (left); p = 0.7830 (right). f, g Western blot and densitometry of MEFs after OHT treatment as indicated vs. control, representative of N = 4 independent experiments; p = 0.0168 (left), p = 0.6857 (right). h Q-RT-PCR in MEFs after OHT treatment for genes as indicated. N = 3 per group; p < 0.0001. i Flow-cytometry based measurement of MRC2 surface expression in MEFs after OHT treatment. N = 4 per group; p = 0.0004. j Representative wide-field immunofluorescence images of MEFs after OHT treatment. k Q-RT-PCR of MRC5 cells transfected with overexpression vectors containing genes as indicated vs. vehicle control (lipofectamine only). N = 4 per group; p = 0.0017 (vs. Veh), p = 0.0029 (vs. GAPDH). l Western blot of MRC5 cells transfected with overexpression vectors containing genes as indicated vs. vehicle control (lipofectamine only). N = 2. Data are shown as the mean ± SEM. Statistics: b paired Student’s t test (two-sided); (d, g - left panel, h, i) unpaired Student’s t test (two-sided); (e, k) one-way ANOVA with post-hoc Tukey testing; (g - right panel) unpaired Mann–Whitney U test (two-sided). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns not significant. Source data are provided as a Source Data file.